Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BeiGene Ltd ( (HK:6160) ) has provided an announcement.
BeOne Medicines Ltd., a Switzerland-based company, has announced a post-effective amendment to its Form S-3 registration statement filed with the U.S. Securities and Exchange Commission. This move allows the company to offer securities on a delayed or continuous basis under Rule 415 of the Securities Act of 1933, potentially enhancing its financial flexibility and market presence.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,789,106
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$236.3B
Learn more about 6160 stock on TipRanks’ Stock Analysis page.